You are here

Article Text

Article menu
Download PDFPDF
LETTER
Mutant K-ras2 in serum
  1. H J N Andreyev1,
  2. R Benamouzig2,
  3. M Beranek3,
  4. P Clarke4,
  5. D Cunningham5,
  6. A R Norman5,
  7. W Giaretti6,
  8. A F P M de Goeij7,
  9. B J Iacopetta8,
  10. E Jullian9,
  11. K Krtolica10,
  12. J Q Lee11,
  13. S T Wang11,
  14. N Lees12,
  15. F Al-Mulla13,
  16. O Muller14,
  17. M Pauly15,
  18. V Pricolo16,
  19. A Russo17,
  20. C Troungos18,
  21. N Urosevic19,
  22. R Ward20
  1. 1Imperial College, London UK
  2. 2Hospital Avicenne, Bobigny, France
  3. 3Charles University Hospital, Hradec Kralove, Czech Republic
  4. 4Institute of Cancer Research, Sutton, UK
  5. 5Royal Marsden Hospital, London UK
  6. 6Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
  7. 7Maastricht University, the Netherlands
  8. 8University of Western Australia, Nedlands, Australia
  9. 9Groupe Hospitalier Cochin-Saint Vincent de Paul, Paris, France
  10. 10Institute of Nuclear Sciences “Vinca” Belgrade, Yugoslavia
  11. 11National Cheng Kung University, Taiwan
  12. 12Wythenshawe Hospital, Manchester, UK
  13. 13Kuwait University, Kuwait
  14. 14Max-Planck-Institut fur Molekulare Physiologie, Dortmund, Germany
  15. 15Centre Universitaire de Luxembourg, Luxembourg
  16. 16Rhode Island Hospital, Brown University, USA
  17. 17University of Palermo, Italy
  18. 18University of Athens, Greece
  19. 19Military Medical Academy, Belgrade, and University of Western Australia, Nedlands, Australia
  20. 20St Vincent’s Hospital, Darlinghurst, Australia
  1. Correspondence to:
    Dr H J N Andreyev, Department of Medicine and Therapeutics, Chelsea and Westminster Hospital, 369 Fulham Rd, London SW10 9NH, UK;
    j.andreyev{at}ic.ac.uk

https://doi.org/10.1136/gut.52.6.915-a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Ryan and colleagues’ careful and well conducted study (Gut 2003;52:101–8) raises once again the interesting issue of whether molecular analysis and knowledge of mutations of the Kirsten ras gene in particular, have a role in the management of patients with colorectal cancer.

    The two RASCAL (Kirsten Ras in Colorectal Cancer Collaborative group) studies1,2 which eventually enrolled data from 4266 patients from 42 centres in 21 countries showed that although the frequency of Kirsten ras mutations at codons 12 and 13 may vary a little between populations, overall they are only present in just over one third of patients. This is significantly less frequent than quoted by Ryan et al. In addition, the RASCAL study also showed that Kirsten ras mutations are …

    View Full Text